Guliyev, M.; Güren, A.K.; Özge, E.; Çolak, R.; Majidova, N.; Alkan Şen, G.; Safarov, S.; Günaltılı, M.; Fidan, M.C.; Gültürk, İ.;
et al. The Impact of Progesterone Receptor Status on Survival Outcomes in Metastatic Breast Cancer Patients Treated with First-Line CDK4/6 Inhibitors. Cancers 2025, 17, 693.
https://doi.org/10.3390/cancers17040693
AMA Style
Guliyev M, Güren AK, Özge E, Çolak R, Majidova N, Alkan Şen G, Safarov S, Günaltılı M, Fidan MC, Gültürk İ,
et al. The Impact of Progesterone Receptor Status on Survival Outcomes in Metastatic Breast Cancer Patients Treated with First-Line CDK4/6 Inhibitors. Cancers. 2025; 17(4):693.
https://doi.org/10.3390/cancers17040693
Chicago/Turabian Style
Guliyev, Murad, Ali Kaan Güren, Emre Özge, Rumeysa Çolak, Nargiz Majidova, Gülin Alkan Şen, Shamkhal Safarov, Murat Günaltılı, Mehmet Cem Fidan, İlkay Gültürk,
and et al. 2025. "The Impact of Progesterone Receptor Status on Survival Outcomes in Metastatic Breast Cancer Patients Treated with First-Line CDK4/6 Inhibitors" Cancers 17, no. 4: 693.
https://doi.org/10.3390/cancers17040693
APA Style
Guliyev, M., Güren, A. K., Özge, E., Çolak, R., Majidova, N., Alkan Şen, G., Safarov, S., Günaltılı, M., Fidan, M. C., Gültürk, İ., Yılmaz, M., Bayoğlu, İ. V., Demirci, N. S., & Alan, Ö.
(2025). The Impact of Progesterone Receptor Status on Survival Outcomes in Metastatic Breast Cancer Patients Treated with First-Line CDK4/6 Inhibitors. Cancers, 17(4), 693.
https://doi.org/10.3390/cancers17040693
